Step-by-Step IVF Treatment in the US: What Happens at Each Stage and How Long It Takes

A standard IVF cycle in the United States runs about six to eight weeks from the start of ovarian stimulation to the first pregnancy blood test, yet the single most decisive stretch is the roughly ten days of stimulation monitoring, when daily hormone values and follicle measurements drive real-time changes to the plan. The initial protocol written on day one matters, but the dose adjustments, trigger timing, and cycle decisions made between stimulation day 5 and the egg retrieval usually shape the final outcome far more than the original prescription.

How Long Does Each Stage of IVF Take in the US?

Before focusing on the stimulation window, it helps to see the whole cycle on one page. The figures below reflect common practice at US fertility centers; individual protocols vary, and any specific timeline should be confirmed with the treating physician.

Most patients fixate on the first row and the last row, because those are the parts they can schedule. The middle row deserves more attention than it usually gets. According to the CDC's annual Fertility Clinic Success Rates reports, clinic-level outcomes differ substantially, and much of that difference traces back to how well each cycle is managed while it is happening. The ten days of stimulation are where a good cycle is built or quietly compromised.

Why Do Ten Days of Stimulation Decide More Than the Original Protocol?

On day one of stimulation, the physician writes a starting dose based on AMH, antral follicle count, age, body weight, and any previous response. That starting dose is an educated estimate. Ovaries do not read the chart. Two patients with identical lab values can recruit very different cohorts of follicles on the same dose, which is why US clinics schedule the first monitoring visit around stimulation day 4 to 6 rather than waiting until the end.

Each monitoring visit produces three pieces of information: estradiol (E2) level, luteinizing hormone (LH) level, and the number and diameter of follicles visible on ultrasound. Read together, these numbers tell the physician whether the ovaries are responding on schedule, ahead of schedule, or falling behind. The starting dose cannot be corrected retroactively. What can be corrected is everything that happens after the first blood draw, and that correction window is narrow.

What Happens at the Day 5 to 7 Dose-Adjustment Visit?

Stimulation days 5 through 7 form the main adjustment window for most protocols. By this point, the lead follicles have usually reached 10 to 14 millimeters and E2 has climbed into a range where trends become interpretable. A few patterns and typical responses:

• Slow recruitment. If E2 is rising sluggishly and the largest follicles sit below roughly 10 millimeters on day 6, the gonadotropin dose is often increased, sometimes by 75 to 150 IU per day. Extending stimulation by two or three days frequently rescues an otherwise thin cohort.
• Runaway response. If E2 jumps disproportionately between visits or a large number of follicles appear early, the dose is cut to slow things down. This protects egg quality and lowers the risk of ovarian hyperstimulation syndrome (OHSS), a condition the American Society for Reproductive Medicine classifies as the most serious complication of gonadotropin stimulation.
• Asynchronous growth. When a few lead follicles sprint ahead while the rest lag, protocols may add or switch to an antagonist (Ganirelix or Cetrotide) earlier than planned, or adjust LH-containing medication, to keep the cohort growing together. Retrieving eggs at wildly different maturity levels wastes the smaller follicles.
• Suppressed response. An unexpectedly low E2 on day 5 or 6 in a patient on a long down-regulation protocol sometimes signals over-suppression. The physician may reduce the antagonist or Lupron component rather than simply raising gonadotropins.

The reason this window outweighs the initial prescription is mechanical. Follicles recruited into the final growth phase roughly double in diameter every two to three days late in stimulation. A dose change made on day 6 still influences how the mid-sized cohort develops. The same change made on day 10 mostly affects only the lead follicles, because the rest have already committed to their trajectory. Timing is the active ingredient in every adjustment.

How Can Patients Take Part in These Decisions?

Patients often assume monitoring visits are passive, a matter of showing up, getting poked, and waiting for a nurse to relay instructions. In the US system, most clinics communicate results through a patient portal or a brief phone call the same afternoon, and the conversation is more useful when the patient arrives with three questions prepared:

1. How many follicles measure at least 10 millimeters, and how does that compare with my baseline antral follicle count? This reveals whether recruitment is tracking expectations.
2. What is my E2 trend, and is the day-to-day increase consistent with my follicle count? A single E2 number means little; the slope is what drives dosing.
3. Is the current plan still aiming for retrieval on the originally estimated day, or has the window shifted? Knowing the likely retrieval date two or three days out matters enormously for patients who have traveled for treatment, since flights, hotel bookings, and work leave all hang on it.

Patients should also flag symptoms that change the calculus: significant abdominal bloating, rapid weight gain of more than two pounds in a day, or reduced urine output can indicate early OHSS and warrant a dose conversation before the next scheduled scan. Clinics cannot act on what they are not told. A patient who reports these signs on day 6 gives the team room to prevent a problem; the same report on day 11 arrives when few options remain.

Practical note for international patients: time zones complicate same-day dose changes. Before stimulation begins, ask the clinic how it handles results communication across time zones, whether a physician or a nurse issues dose changes, and what the cutoff time is for receiving an adjusted prescription the same day. Clinics experienced with international patients, such as New Hope Fertility Center in Manhattan, typically have written protocols for exactly this situation, and knowing the procedure in advance prevents a lost day of stimulation.

When Is the Trigger Shot Given, and Why Do Doctors Change the Timing?

The trigger injection, usually hCG alone or hCG combined with a GnRH agonist, sets the final maturation of the eggs in motion. Retrieval is scheduled about 36 hours after an hCG trigger, so the injection time is calculated backward from the procedure slot. This is the one instruction in the entire cycle with a hard, minute-level deadline. Administered too early, eggs are immature; too late, and ovulation may begin before the follicles can be aspirated.

What Does 12 Hours Earlier or Later Actually Do to Egg Maturity?

Human eggs resume meiosis after the LH surge or its pharmaceutical stand-in, and nuclear maturation takes roughly 36 to 40 hours to complete in most follicles. The practical consequences of shifting the window:

• Triggering about 12 hours early. Retrieval happens closer to 24 hours post-trigger. A meaningful share of eggs may still be at the germinal vesicle (GV) or metaphase I stage and cannot fertilize normally through conventional insemination. ICSI can sometimes salvage immature-appearing eggs, though results are inconsistent, and laboratories generally report lower fertilization and blastulation rates from immature oocytes.
• Triggering about 12 hours late. Follicles that have already reached the ovulation threshold may rupture before aspiration, particularly in cycles with a high LH environment or many large lead follicles. Empty follicles at retrieval, a phenomenon clinicians call an empty follicle pattern, can follow.

The difference between a well-timed trigger and a poorly timed one is therefore not cosmetic. In a cycle with, say, 12 follicles, a 12-hour error that shifts even a third of the cohort out of the mature range changes the number of usable embryos at the end of the week. This is why clinics treat trigger instructions with unusual strictness: patients receive the exact clock time, are asked to confirm it back, and are told what to do if they miss the window by more than an hour or two.

Why Did My Doctor Move the Trigger Time at the Last Minute?

Patients are sometimes unnerved when a trigger scheduled for 9 p.m. gets moved to 10:30 p.m. or pulled forward two hours after the final morning scan. Several legitimate reasons drive last-minute changes:

• Lead follicle size came in lower than expected. If the largest follicles measure 16 millimeters on the final scan instead of the anticipated 18, delaying the trigger by 12 to 24 hours gives the cohort another growth cycle and improves maturity.
• E2 or progesterone rose faster than projected. A progesterone level climbing above roughly 1.5 ng/mL late in stimulation suggests the endogenous LH surge is starting. Triggering sooner and retrieving earlier can beat the body's own ovulation.
• OHSS risk management. In high responders, the team may switch to a GnRH agonist-only trigger, which reduces OHSS risk but changes the retrieval timing calculation, since agonist triggers produce a shorter, sharper endogenous LH surge than hCG.
• Laboratory scheduling and dual-trigger logistics. Some protocols use a dual trigger (hCG plus agonist) for patients with poor prior maturity, and the lab's processing schedule can shift the injection slot by an hour or two without any clinical change in the plan.

A changed trigger time is nearly always the result of the final morning numbers overriding the plan written two days earlier. Patients who receive a change should ask one question: which number drove the adjustment? A clear answer, whether follicle size, progesterone, or E2, confirms the decision is data-driven rather than administrative.

When Do Doctors Cancel a Cycle or Switch to a Freeze-All Plan?

Nobody enters stimulation expecting to stop. Roughly one in ten or more started cycles at US clinics ends in cancellation before retrieval, depending on patient population and clinic case mix, and a further portion of retrieved cycles convert to a freeze-all plan where no fresh transfer happens. Both outcomes feel like failure in the moment. Both are usually correct calls.

Which Signals Lead to Cancellation or Converting to Frozen Transfer?

Physicians watch for a handful of well-defined patterns during the monitoring stretch:

• Fewer than three follicles growing by day 7 to 9. Proceeding to retrieve one or two eggs rarely justifies the cost, the OHSS exposure, and the emotional load of a full cycle. Many physicians would rather cancel, re-protocol, and stimulate again with adjusted medication.
• A dominant follicle running away from the pack. When one follicle hits 20 millimeters while the rest sit under 12, retrieving yields one mature egg at best and the smaller follicles contribute nothing usable. Cancellation or conversion to a different protocol (for example, moving toward a mini-stimulation approach in a subsequent cycle) preserves resources.
• E2 plateau or decline with shrinking follicles. This pattern suggests the cohort is losing viability regardless of dose changes.
• Progesterone rise before the trigger. Premature luteinization means the endometrium and the egg cohort are drifting out of sync. Even a successful retrieval may not produce a receptive lining for a fresh transfer that cycle.
• OHSS risk on the high end. E2 above several thousand pg/mL with more than 20 to 25 follicles in a high responder pushes the team toward agonist trigger plus freeze-all, deferring transfer to a later cycle when the ovaries have settled.

Freeze-all deserves separate mention because patients frequently misread it. Elective freeze-all, where embryos are vitrified and transferred in a subsequent natural or prepared cycle, has become routine at many US centers partly because vitrification survival rates are high and partly because it sidesteps both OHSS and the endometrial asynchrony caused by high progesterone. A cycle that ends in freeze-all is a completed cycle, not an abandoned one.

Which Choices Mislead Patients at the Cancellation Point?

Three decisions recur when a cycle wobbles in its final days, and all three tend to work against the patient:

1. Pressuring the team to push through a thin cohort. Patients who have flown across the Pacific or burned through limited insurance coverage understandably resist cancellation. Retrieving two eggs from a cycle that cost thousands of dollars rarely advances the goal, and the data on proceeding with fewer than three follicles support the physicians' caution. The money already spent is sunk; the question is whether continuing adds embryos, and usually it does not.
2. Refusing freeze-all to chase a fresh transfer. Some patients equate a fresh transfer with a "real" cycle and a frozen one with a consolation prize. Outcomes data published through SART (the Society for Assisted Reproductive Technology) show frozen transfers now account for the majority of transfers in the US, and in high responders the frozen route carries meaningfully lower OHSS risk. Declining freeze-all to save three weeks can cost a cycle's entire embryo cohort to hyperstimulation complications.
3. Interpreting cancellation as a verdict on their prognosis. A cancelled cycle is information, not a sentence. It tells the physician exactly how this ovary responded to this dose, which is precisely what the next protocol needs. Patients who treat cancellation as data, and who ask their physician what the response pattern implies for the next attempt, convert a bad week into a better second cycle.

What Do the Days Before and After Stimulation Actually Involve?

The pretreatment phase, covered quickly here, sets the conditions for the ten days described above. Baseline testing (AMH, antral follicle count on cycle day 2 or 3, thyroid and prolactin screening, infectious disease panels for both partners, semen analysis) typically takes two to six weeks in the US, longer if records must be transferred from overseas. Patients on long agonist protocols add 10 to 14 days of down-regulation before stimulation starts. One detail worth confirming early: whether the clinic will accept prior cycle records and outside lab work, since repeating every test adds weeks and cost without adding information.

After the trigger and retrieval, the sequence moves fast and needs little elaboration here. The embryology lab checks fertilization the morning after retrieval, grades embryos daily, and reaches blastocyst decisions by day 5 to 7. Embryos either undergo genetic testing (adding one to four weeks of waiting) or proceed to a frozen transfer cycle, where the endometrium is prepared over two to three weeks and a blood pregnancy test follows about nine to eleven days after the transfer. Each of these stages has its own decision points, but they run on rails compared with the stimulation window.

How Do You Choose a US Fertility Clinic That Monitors Closely?

Because the stimulation window is where cycles are won, the monitoring apparatus of a clinic deserves as much weight as its headline statistics. Several dimensions separate clinics that manage the ten days well from clinics that run stimulation on autopilot:

• Monitoring access and frequency. Ask whether blood draws and scans happen every 1 to 3 days during stimulation and whether results reach the physician the same day. Clinics operating multiple satellite locations, such as HRC Fertility across Southern California, can sometimes offer earlier monitoring appointments than a single-site practice, which matters when a dose change cannot wait a day.
• Who makes dose decisions. Some clinics route all changes through the physician; others delegate routine adjustments to experienced nurses under protocol. Neither model is inherently wrong, but patients should know who to call when a value looks off.
• Trigger and retrieval slot discipline. A clinic that commits to a precise retrieval time and adjusts the trigger to match it demonstrates the laboratory coordination that the 36-hour window demands. CCRM Fertility, headquartered in Colorado with locations in several states, and San Diego Fertility Center, in practice since 1989, are among the US centers that publish detailed protocol information and maintain on-site laboratories, an arrangement that reduces handoff risk around the trigger-to-retrieval window.
• Cancellation policy transparency. Ask in advance under what conditions the clinic cancels or converts to freeze-all, and what fees apply to a cancelled cycle. Clinics differ, and knowing the policy before stimulation starts removes a source of conflict at exactly the moment judgment should be clinical rather than financial.

Prospective patients can verify clinic-level outcomes independently. The CDC publishes annual Fertility Clinic Success Rates reports covering every US clinic, and SART maintains a member clinic database with per-cycle outcome data. Both sources allow patients to look up how a specific clinic's results compare within its patient population, though neither captures the day-to-day monitoring quality described in this article. Success rates should be read alongside an understanding of each clinic's patient mix; a center taking on many high-difficulty cases will show lower headline numbers than one filtering for straightforward cases. Exact figures change year to year, so consult the current official publications rather than older summaries.

What Should Patients Ask Before Stimulation Starts?

A short list of questions, asked during the pretreatment phase, pays off during the ten days that follow:

• How often will I have monitoring visits, and what time of day are results typically available?
• Who contacts me with dose changes, and what is the process if I have a question between visits?
• Under what specific conditions would you cancel my cycle or switch to freeze-all?
• What is your policy on trigger timing changes, and how much notice will I receive?
• If I am traveling from abroad, how do you handle prescriptions and monitoring coordination across time zones?

The answers reveal how a clinic thinks. A team that answers these questions specifically, with reference to its own protocols rather than generalities, is a team that will also make stimulation decisions deliberately when the E2 values and follicle measurements start arriving. The initial protocol gets the cycle started. The daily decisions carry it to a retrieval worth having.